RxDoctor Payments Data

Peter Kringstein, MD

Cardiovascular Disease · Rochester, NYNPI 1134124456

Payments from drug & device makers

$1,298in general payments, 2019–2025

Across 50 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$270
  • Edwards Lifesciences$178
  • E.r. Squibb & Sons, L.L.C.$175
  • Novo Nordisk$161
  • Boehringer Ingelheim$156
  • Pfizer$79
  • plus $279 from 9 others

What the payments were for

  • Food & beverage$1,298100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,298 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$62,076
Medicare patients
450
Services billed
1,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban441$523,327
XareltoRivaroxaban129$151,810
EntrestoSacubitril/Valsartan132$135,005
FarxigaDapagliflozin Propanediol76$74,487
JardianceEmpagliflozin48$50,235
Praluent PenAlirocumab55$43,655
Repatha SureclickEvolocumab15$19,548
Dofetilide43$10,546
Metoprolol Succinate637$10,174
Atorvastatin Calcium496$7,819
NexletolBempedoic Acid12$6,280
Ezetimibe137$6,090
Propafenone Hcl ErPropafenone Hcl18$5,792
Diltiazem 24hr Er (Cd)Diltiazem Hcl90$3,860
Diltiazem 12hr ErDiltiazem Hcl15$3,692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$79$523,327441 claims
Johnson & JohnsonXarelto$13$151,810129 claims
NovartisEntresto$270$135,005132 claims
Boehringer IngelheimJardiance$156$50,23548 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →